{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=72", "query": { "intervention": "cyclophosphamide", "page": 72 }, "page_size": 10 }, "pagination": { "page": 72, "page_size": 10, "total_count": 2806, "total_pages": 281, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=73&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=71&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T09:22:04.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07524530", "title": "Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Core Binding Factor Alpha Subunits", "Hematologic Neoplasms", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Hematopoietic stem cells", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "4 Years to 70 Years" }, "enrollment_count": 102, "start_date": "2026-11-10", "completion_date": "2036-06-01", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07524530" }, { "nct_id": "NCT00478244", "title": "Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epidermolysis Bullosa" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "hematopoietic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 7, "start_date": "2007-04", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478244" }, { "nct_id": "NCT03318900", "title": "T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COL6A3 Positive", "HLA-A*0201 Positive Cells Present", "PRAME Positive", "Recurrent Ovarian Carcinoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "CD8-Positive T-Lymphocyte", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Utomilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 5, "start_date": "2018-09-04", "completion_date": "2023-12-20", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03318900" }, { "nct_id": "NCT06180863", "title": "Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "oral azacitidine (CC-486)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2023-11", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06180863" }, { "nct_id": "NCT01652092", "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "SCID", "Omenn's Syndrome", "Reticular Dysgenesis", "Wiskott-Aldrich Syndrome", "Bare Lymphocyte Syndrome", "Common Variable Immunodeficiency", "Chronic Granulomatous Disease", "CD40 Ligand Deficiency", "Hyper IgM Syndrome", "X-linked Lymphoproliferative Disease", "Hemophagocytic Lymphohistiocytosis", "Griscelli Syndrome", "Chediak-Higashi Syndrome", "Langerhan's Cell Histiocytosis" ], "interventions": [ { "name": "Alemtuzumab 0.3 mg", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Fludarabine phosphate 40 mg", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab 0.2 mg", "type": "DRUG" }, { "name": "Fludarabine phosphate 30 mg", "type": "DRUG" }, { "name": "MESNA", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 57, "start_date": "2012-09-04", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652092" }, { "nct_id": "NCT00017641", "title": "Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "CD34+ Peripheral Blood Stem Cell Reinfusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Northwestern Memorial Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "0 Years to 59 Years" }, "enrollment_count": 10, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 2, "location_summary": "Chicago, Illinois • Madison, Wisconsin", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017641" }, { "nct_id": "NCT03096782", "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Leukemia", "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chemotherapy-Related Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Hodgkin Lymphoma", "Langerhans Cell Histiocytosis", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Myelodysplastic Syndrome", "Small Lymphocytic Lymphoma", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2017-10-13", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03096782" }, { "nct_id": "NCT00043979", "title": "Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "F-18 Fluorodeoxyglucose", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell donation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "5 Years to 35 Years" }, "enrollment_count": 60, "start_date": "2002-09-19", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043979" }, { "nct_id": "NCT00003288", "title": "Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003288" }, { "nct_id": "NCT00304083", "title": "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis Type 1", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 48, "start_date": "2005-12", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-11-06T09:22:04.498Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304083" } ] }